Clinical trial NCT03038230: MCLA-117 in Acute Myelogenous Leukemia
Official title: A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Keywords: human bispecific full length IgG antibody, CLEC12A, CD3
MCLA-117
First in Human
Antibodies, Bispecific
Immunologic Factors
relapsed, refractory patient
AML, minimal residual disease (MRD)
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
CD34+CD38
T-cell recruiting
Lead sponsor: Merus N.V.
Sponsor class: INDUSTRY
First posted: 2017-01-31
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.

Detailed description: Study Design :

This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1 consists of dose escalation cohorts and Part 2 is a dose expansion cohort.

The study population will include adult AML patients (and all subtypes of AML, except for APL) with relapse or refractory disease and newly diagnosed elderly untreated AML patients with high risk cytogenetics. In addition, very high-risk MDS patients with relapsed or refractory disease are eligible.

In Part 1, dose escalations cohorts are followed until dose-limiting toxicity (DLT) or a maximum tolerated dose (MTD) or RecommendedPart2Dose (RP2D) is defined. Dose escalation decisions will be made by the Data Review Committee and will be primarily guided by safety data observed through the end of Cycle 1, as well as on-going assessment of safety beyond Cycle 1 in later cohorts.

Part 2 will begin once the MTD or RP2D is determined in Part 1. Part 2 will further characterize the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), immunogenicity and to assess preliminary efficacy of MCLA-117. This part will enroll approximately 30 evaluable patients (defined as evaluable for first efficacy assessment).

For both parts, the study consists of 3 periods: a Screening period (up to 28 days prior to the first dose of study drug); a Treatment period (first dose of study drug until the last dose of study drug with treatment cycles of 28 days); and a Follow Up period (through 30 days after the last dose and quarterly checks for survival data for up to 1 year). Participants' safety will be monitored throughout the study. Patients will be permitted to receive MCLA-117 beyond Cycle 1 if conditions allow this.

Number of Sites:

Approximately 15 centers in five countries are estimated to be involved during Parts 1 and 2 of the study. Additional sites may be added to ensure there is an acceptable enrollment rate or to replace non-enrolling/withdrawn sites.

Eligibility criteria: Inclusion Criteria:

1. Male or female age ≥18 years old;
2. Signed informed consent form
3. One of the two following:

   i) AML either de novo or secondary \[any subtype except acute promyelocytic leukemia (APL)\] who either:
   1. are in relapse to standard therapy following an initial response
   2. failed primary induction therapy with no CR (failed ≥2 courses of intensive induction therapy. Intensive chemotherapy defined as an intensity of ≥ 5+2)
   3. newly diagnosed untreated AML in patients ≥ 65 years of age with high risk cytogenetics, if they are not candidates for standard available induction chemotherapy
   4. AML secondary to MDS, either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;
   5. Relapsed or refractory AML unfit for intensive chemotherapy previously treated with a low intensity regimen (e.g. low dose Ara-c, hypomethylating agent, etc.) including Venetoclax for at least 2 cycles;

   OR ii) MDS patients who meet the following criteria: very high-risk disease (IPSS-R score \> 6, Greenberg et al., 2012), either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;
4. Must have baseline BM sample taken by BMA/BMB within 28 days prior to first dose of MCLA-117 for CLEC12A detection;
5. Estimated life expectancy of at least 8 weeks;
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
7. Significant toxicities incurred as a result of previous anti-cancer therapy resolved to ≤ Grade 1 (NCI-CTCAE version 4.03);
8. Acceptable laboratory values at screening;
9. Male patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least 6 months after if their sexual partners are women of child bearing potential (WOCBP).
10. WOCBP must be using highly effective and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 6 months after the study ;
11. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug.
12. Peripheral blast count \</= 30,000/mm3 at the time of initiation of infusion on Cycle 1 Day 1.
13. Able and willing to comply with all study procedures.

Exclusion Criteria:

1. Diagnosis of chronic myelogenous leukemia in blast crisis;
2. Prior hematopoietic stem cell transplantation (this exclusion applies for dose escalation Part 1 and Cohort A of Part 2);
3. For patients in Cohort B of Part 2, prior hematopoietic stem cell transplantation is allowed under certain circumstances.
4. Treatment with anticancer medications, investigational drugs or radiotherapy is allowed within 2 weeks or 5 half-lives prior to start of MCLA-117;
5. Previous receipt of live vaccines in the 4 weeks prior to study drug administration;
6. Chronic concurrent need of use of corticosteroids \> 10 mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);
7. Use of immunosuppressant medications within 4 weeks of MCLA-117 administration;
8. Clinically active central nervous system (CNS) leukemia;
9. Patients who are pregnant or lactating;
10. Patients with an active infection or with an unexplained fever during screening or on the first scheduled day of dosing;
11. Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
12. Patients with known HIV, hepatitis B or C;
13. Patients with New York Heart Association Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) \< 50%, or significant uncontrolled cardiac disease, current diagnosis of unstable angina, uncontrolled congestive heart failure, new myocardial infarction, or ventricular arrhythmia requiring medication;
14. Prior malignancy (other than basal cell carcinoma and cervical in situ carcinoma) unless treated with a curative intend and without evidence of malignant disease for 1 year before screening. Patients with prior hematologic malignancies that have progressed to AML (such as Myelodysplastic syndrome, myeloproliferative neoplasms, bi-phenotypic leukemias, AcuteLymphocyticLeukemia) or AML that has relapsed are eligible;
15. Urinary protein \>2+ possibly indicative of renal disease. If the 24 hours urine protein shows a result of \< 100 mg protein, subject can be eligible;
16. Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results;
17. WOCBP or males with a WOCB partners not willing to use highly effective and medically accepted methods of contraception for 6 months after last study drug administration.
18. Need for concurrent other cytoreductive chemotherapy.

Primary outcomes:
measure: Number of participants with Dose Limiting Toxicities (DLT)
timeFrame: 28 days
Secondary outcomes:
measure: Maximum plasma concentration [Cmax]
timeFrame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
measure: Clearance of plasma
timeFrame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
measure: Volume of distribution at steady state [Vss]
timeFrame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
measure: Time to reach maximum plasma concentration [Tmax]
timeFrame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
measure: Half-life [t1/2]
timeFrame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
measure: Area under the concentration versus time curve from time zero to time t [AUC0-t]
timeFrame: 1 week
measure: Incidence of AntiDrugAntibodies (ADA) against MCLA-117
timeFrame: 24 months
measure: Serum titer of ADAs against MCLA-117
timeFrame: Day 1 of each cycle
measure: Serum titer of ADAs against MCLA-117
timeFrame: Day 28 of each cycle
measure: Cytokine levels
timeFrame: Cycle 1: Day 1, 4, 8 and 28 at predose, 4h and 24h after end of infusion
measure: Number of myeloblasts
timeFrame: Day 1 of every cycle and through study completion, an average of 2 months
measure: Objective response
timeFrame: Day 1 of every cycle and through study completion, an average of 2 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: Houston
country: United States
facility: The University of Texas, MD Anderson Cancer Center
state: Texas
city: Antwerpen
country: Belgium
facility: Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
city: Villejuif Cedex
country: France
facility: Institut Gustave Roussy
state: Ile-de-France
city: Rome
country: Italy
facility: Fondazione Policlinico Tor Vergata
city: Amsterdam
country: Netherlands
facility: Amsterdam UMC, location VUmc
state: Noord-Holland
city: Rotterdam
country: Netherlands
facility: Erasmus MC
state: Zuid-Holland
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen
Study officials:
affiliation: Independent Protocol Advisor
name: Jorge Cortes, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: